Latest Insider Transactions at Madrigal Pharmaceuticals, Inc. (MDGL)

MDGL Quotes by TradingView

This section provides a real-time view of insider transactions for Madrigal Pharmaceuticals, Inc. (MDGL). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of MADRIGAL PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of MADRIGAL PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.

Insider Transaction List

Date Insider Transaction Ownership Type Shares Traded Value / Price
Apr 10 2025
Richard S Levy Director
BUY
Exercise of conversion of derivative security
Direct
9,470 +31.62%
$615,550 $65.06 P/Share
Mar 13 2025
Fred B Craves Director
SELL
Open market or private sale
Direct
7,742 -0.27%
$2,523,892 $326.58 P/Share
Mar 13 2025
Fred B Craves Director
BUY
Exercise of conversion of derivative security
Direct
7,742 +2.12%
$503,230 $65.06 P/Share
Mar 12 2025
Fred B Craves Director
SELL
Open market or private sale
Direct
7,728 -0.44%
$2,565,696 $332.58 P/Share
Mar 12 2025
Fred B Craves Director
BUY
Exercise of conversion of derivative security
Direct
7,728 +1.07%
$680,064 $88.06 P/Share
Mar 10 2025
Mardi Dier SVP and CFO
SELL
Open market or private sale
Direct
258 -2.41%
$83,334 $323.04 P/Share
Mar 10 2025
Jacqualyn A Fouse Director
BUY
Grant, award, or other acquisition
Direct
894 +50.0%
-
Mar 05 2025
William John Sibold President and CEO
BUY
Grant, award, or other acquisition
Direct
13,066 +10.02%
-
Mar 05 2025
Robert E. Waltermire Senior VP, Chief Pharma Dev.
BUY
Grant, award, or other acquisition
Direct
2,061 +26.25%
-
Mar 05 2025
Robert E. Waltermire Senior VP, Chief Pharma Dev.
SELL
Open market or private sale
Direct
14,113 -14.66%
$4,798,420 $340.42 P/Share
Mar 05 2025
Mardi Dier SVP and CFO
BUY
Grant, award, or other acquisition
Direct
3,784 +26.13%
-
Mar 05 2025
Rebecca Taub Pres., R&D, and CMO
BUY
Grant, award, or other acquisition
Direct
4,382 +0.94%
-
Mar 05 2025
Shannon T Kelley General Counsel
BUY
Grant, award, or other acquisition
Direct
3,187 +23.32%
-
Mar 05 2025
Carole Huntsman Chief Commercial Officer
BUY
Grant, award, or other acquisition
Direct
3,386 +22.02%
-
Mar 03 2025
Shannon T Kelley General Counsel
SELL
Open market or private sale
Direct
415 -5.39%
$139,025 $335.0 P/Share
Mar 03 2025
Mardi Dier SVP and CFO
SELL
Open market or private sale
Direct
1,961 -11.72%
$635,364 $324.72 P/Share
Mar 03 2025
Carole Huntsman Chief Commercial Officer
SELL
Open market or private sale
Direct
1,834 -2.11%
$592,382 $323.86 P/Share
Feb 28 2025
Robert E. Waltermire Senior VP, Chief Pharma Dev.
SELL
Open market or private sale
Direct
1,227 -12.86%
$418,407 $341.27 P/Share
Feb 27 2025
William John Sibold President and CEO
BUY
Exercise of conversion of derivative security
Direct
50,000 +32.4%
-
Feb 27 2025
Kenneth Bate Director
SELL
Open market or private sale
Direct
20,000 -21.4%
$7,100,000 $355.92 P/Share
Feb 27 2025
Kenneth Bate Director
BUY
Exercise of conversion of derivative security
Direct
20,000 +31.84%
$1,220,000 $61.86 P/Share
Feb 27 2025
James M Daly Director
SELL
Open market or private sale
Direct
15,470 -38.4%
$5,368,090 $347.74 P/Share
Feb 27 2025
James M Daly Director
BUY
Exercise of conversion of derivative security
Direct
15,470 +35.54%
$1,361,360 $88.06 P/Share
Jan 24 2025
Carole Huntsman Chief Commercial Officer
SELL
Open market or private sale
Direct
347 -3.22%
$116,245 $335.24 P/Share
Jan 24 2025
William John Sibold President and CEO
SELL
Open market or private sale
Direct
1,584 -2.83%
$530,640 $335.24 P/Share
Jan 24 2025
Rebecca Taub Pres., R&D, and CMO
SELL
Open market or private sale
Direct
648 -0.14%
$217,080 $335.24 P/Share
Jan 24 2025
Robert E. Waltermire Senior VP, Chief Pharma Dev.
SELL
Open market or private sale
Direct
103 -2.04%
$34,505 $335.24 P/Share
Jan 17 2025
Shannon T Kelley General Counsel
SELL
Open market or private sale
Direct
277 -3.47%
$75,621 $273.41 P/Share
Jan 17 2025
Rebecca Taub Pres., R&D, and CMO
SELL
Open market or private sale
Direct
1,689 -0.37%
$461,097 $273.41 P/Share
Jan 17 2025
Robert E. Waltermire Senior VP, Chief Pharma Dev.
SELL
Open market or private sale
Direct
442 -8.04%
$120,666 $273.41 P/Share
Dec 03 2024
Fred B Craves Director
SELL
Open market or private sale
Indirect
3,600 -12.8%
$1,134,000 $315.55 P/Share
Nov 25 2024
Fred B Craves Director
SELL
Open market or private sale
Indirect
3,400 -9.91%
$1,190,000 $350.39 P/Share
Nov 21 2024
Carole Huntsman Chief Commercial Officer
SELL
Open market or private sale
Direct
688 -6.0%
$217,408 $316.92 P/Share
Nov 07 2024
Richard S Levy Director
SELL
Open market or private sale
Direct
5,000 -31.23%
$1,750,000 $350.0 P/Share
Nov 07 2024
Richard S Levy Director
BUY
Exercise of conversion of derivative security
Direct
5,000 +23.8%
$35,000 $7.36 P/Share
Nov 01 2024
Richard S Levy Director
SELL
Open market or private sale
Direct
5,000 -8.77%
$1,505,000 $301.97 P/Share
Nov 01 2024
Richard S Levy Director
BUY
Exercise of conversion of derivative security
Direct
5,000 +23.8%
$35,000 $7.36 P/Share
Sep 13 2024
Fred B Craves Director
SELL
Bona fide gift
Direct
15,000 -4.0%
-
Sep 09 2024
William John Sibold President and CEO
SELL
Open market or private sale
Direct
6,363 -10.22%
$1,546,209 $243.83 P/Share
Aug 15 2024
Shannon T Kelley General Counsel
BUY
Grant, award, or other acquisition
Direct
5,215 +39.52%
-
Jun 25 2024
Kenneth Bate Director
BUY
Grant, award, or other acquisition
Direct
714 +27.19%
-
Jun 25 2024
Fred B Craves Director
BUY
Grant, award, or other acquisition
Direct
714 +0.19%
-
Jun 25 2024
Paul A Friedman
BUY
Grant, award, or other acquisition
Direct
714 +0.38%
-
Jun 25 2024
Richard S Levy Director
BUY
Grant, award, or other acquisition
Direct
714 +6.09%
-
Jun 25 2024
James M Daly Director
BUY
Grant, award, or other acquisition
Direct
714 +27.19%
-
Jun 25 2024
Baker Bros. Advisors LP
BUY
Grant, award, or other acquisition
Indirect
2,856 +0.42%
-
Jun 14 2024
Robert E. Waltermire Senior VP, Chief Pharma Dev.
SELL
Open market or private sale
Direct
1,900 -25.68%
$532,000 $280.0 P/Share
Jun 14 2024
Robert E. Waltermire Senior VP, Chief Pharma Dev.
BUY
Exercise of conversion of derivative security
Direct
1,900 +20.43%
$165,300 $87.09 P/Share
Jun 12 2024
Robert E. Waltermire Senior VP, Chief Pharma Dev.
SELL
Open market or private sale
Direct
2,000 -26.67%
$570,000 $285.0 P/Share

Track Institutional and Insider Activities on MDGL

Follow MADRIGAL PHARMACEUTICALS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MDGL shares.

Notify only if
Any

Insider Trading

Get notified when an Madrigal Pharmaceuticals, Inc. insider buys or sells MDGL shares.

Notify only if
Any
Any
P - Open market or private purchase×
S - Open market or private sale×
V - Transaction voluntarily reported earlier than required×
A - Grant, award, or other acquisition×
D - Sale (or disposition) back to the issuer×
F - Payment of exercise price or tax liability×
I - Discretionary transaction×
M - Exercise of conversion of derivative security×
C - Conversion of derivative security×
E - Expiration of short derivative position×
H - Expiration (or cancellation) of long derivative position with value received×
O - Exercise of out-of-the-money derivative securities×
X - Exercise of in-the-money or at-the-money derivatives securities×
G - Bona fide gift×
L - Small Acquisition×
W - Acquisition or disposition by will or laws×
Z - Deposit into or withdrawal from voting trust×
J - Other acquisition or disposition×
K - Transaction in equity swap or similar instrument×
U - Disposition due to a tender of shares in a change of control transaction×
20 item(s) selected

News

Receive news related to MADRIGAL PHARMACEUTICALS, INC.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on MDGL